Literature DB >> 7762235

[Outcomes and prognosis of diseases caused by Inkoo and Tahyna viruses].

V G Demikhov.   

Abstract

The outcomes of diseases caused by Inkoo and Tahyna viruses are favorable. No lethal cases were observed. Altogether 16.7% of convalescents after the febrile form of the disease and 30.7% convalescents after the neuroinfections form develop 1 to 2.5 years after the disease (follow-up period) asthenoneurologic disturbances and microfocal neurologic symptoms. Blood sera of 118 patients with chronic neurologic diseases were tested in the neutralization test with Inkoo and Tahyna viruses. Summary antibodies to Inkoo and Tahyna viruses were detected in 26 (70.3%) of 37 examined patients with disseminated encephalomyelitis. The findings point to necessity of further study of the possible role of California encephalitis group viruses in the etiology of chronic neuroviral infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7762235

Source DB:  PubMed          Journal:  Vopr Virusol        ISSN: 0507-4088


  4 in total

1.  Acute Human Inkoo and Chatanga Virus Infections, Finland.

Authors:  Niina Putkuri; Anu Kantele; Lev Levanov; Ilkka Kivistö; Markus Brummer-Korvenkontio; Antti Vaheri; Olli Vapalahti
Journal:  Emerg Infect Dis       Date:  2016-05       Impact factor: 6.883

2.  Seroprevalence and Risk Factors of Inkoo Virus in Northern Sweden.

Authors:  Magnus Evander; Niina Putkuri; Mats Eliasson; Olivia Wesula Lwande; Olli Vapalahti; Clas Ahlm
Journal:  Am J Trop Med Hyg       Date:  2016-02-29       Impact factor: 2.345

3.  The transmission ecology of Tahyna orthobunyavirus in Austria as revealed by longitudinal mosquito sampling and blood meal analysis in floodplain habitats.

Authors:  Jeremy V Camp; Edwin Kniha; Adelheid G Obwaller; Julia Walochnik; Norbert Nowotny
Journal:  Parasit Vectors       Date:  2021-10-30       Impact factor: 3.876

Review 4.  Emerging orthobunyaviruses associated with CNS disease.

Authors:  Arthur Wouter Dante Edridge; Lia van der Hoek
Journal:  PLoS Negl Trop Dis       Date:  2020-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.